Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 07:15 AM
November 2025
In this educational discussion, Lindsay Yoder, PA from Indiana University Health dives into one of the fastest-evolving areas in hepatology—metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated alcohol-related liver disease (MetALD). Using a real-world case study, Lindsay explains how to identify, classify, and manage patients with overlapping metabolic and alcohol-related risk factors. She outlines how to interpret key non-invasive assessments such as FibroScan CAP scores, PEth testing, and ANI scoring, while emphasizing how alcohol intake—even at moderate levels—can accelerate liver fibrosis in patients with metabolic dysfunction. The session also reviews diagnostic thresholds, treatment strategies including lifestyle modification, Mediterranean diet, and resmetirom, and the importance of counseling patients on alcohol reduction. Whether you’re a hepatology APP or primary care provider, this talk offers a clear, practical framework for navigating MASLD, MetALD, and the new nomenclature shaping liver disease management today.
Related Webcast
Webcast: Comparing F3 and F4 Fibrosis With Jennifer Geremia
August 2025
In this GHAPP MASLD Community Network session, Jennifer Geremia, PA-C from Boston, discusses the critical differences between F3 fibrosis and F4 cirrhosis in patients with MASLD (Metabolic Associated Steatotic Liver Disease) and MASH (Metabolic Associated Steatohepatitis). Using a detailed case study, she outlines how non-invasive tests (NITs) such as FIB-4, FibroScan, CAP score, and ELF testing can help differentiate fibrosis stages and guide patient management. The discussion highlights when to consider advanced testing, the role of resmetirom (Rezdiffra) in eligible F2–F3 patients, and why treatment strategies differ for those with F4 cirrhosis, including the need for HCC surveillance, portal hypertension evaluation, and variceal screening. Jennifer also emphasizes lifestyle modifications, metabolic risk factor control, and multidisciplinary care as essential components of managing advanced liver disease. This presentation provides valuable insights for GI, hepatology, and primary care providers navigating the nuances of fibrosis staging and treatment decisions in 2025.
Watch Now
Live From GHAPP National: Abnormal Liver Chemistry Workup
November 2025
In this session, Jeremy Davis, ACNP from Shreveport, Louisiana, breaks down a practical, step-by-step approach to evaluating abnormal liver chemistries. Using a real patient case, he reviews how to interpret ALT, AST, ALP, bilirubin, MCV, and GGT patterns; when to suspect hepatocellular, cholestatic, or mixed injury; and how to build an efficient differential using history, medications, alcohol assessment, and key labs (viral hepatitis panel, autoimmune markers, iron studies, Wilson disease testing, alpha-1 antitrypsin phenotype). He also highlights the role of ultrasound, MRCP, non-invasive fibrosis tests (FIB-4, ELF, VCTE), and when biopsy is needed. A practical, clinic-ready guide for APPs and clinicians assessing elevated liver enzymes and differentiating MASLD, alcohol-related disease, DILI, and other common etiologies.
Watch Now
Webcast: MASLD vs MetALD With Kelly Smeester
September 2025
In this session from the GHAPP MASLD Community Network, Kelly Smeester, PA-C at South Denver Gastroenterology, reviews a patient case to highlight the overlap between metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction plus alcohol-associated liver disease (MetALD). Using real-world labs, FibroScan values, CAP scores, and the PEth biomarker, she explains how clinicians can distinguish MASLD from MetALD and alcohol-related liver disease. The discussion covers key metabolic risk factors such as PCOS, hypertension, and hyperlipidemia, the impact of moderate alcohol intake, and how these drivers accelerate fibrosis progression and increase the risk of decompensation. Viewers will learn how to evaluate alcohol use through standardized definitions, clinical questionnaires, and biomarkers, as well as best practices for patient education, lifestyle counseling, and management, including diet, exercise, pharmacologic options, and hepatocellular carcinoma (HCC) surveillance. This case-based talk emphasizes why accurate diagnosis and objective assessment of alcohol consumption are essential for both clinical care and research in steatotic liver disease.
Watch Now
Webcast: MASLD Pharmacotherapy With Emily Przybyl
October 2025
In this session, Emily Przybyl, PA-C from Erie County Medical Center in Buffalo, NY, explores current pharmacologic strategies for managing metabolic dysfunction–associated steatohepatitis (MASH) and metabolic dysfunction–associated steatotic liver disease (MASLD). She reviews the foundation of treatment—lifestyle modification, weight-loss interventions, and cardiovascular risk reduction—before detailing the evidence and clinical considerations for GLP-1 receptor agonists, vitamin E, pioglitazone, and the newly approved resmetirom. Emily discusses dosing strategies, histologic outcomes from major trials, and safety considerations including drug interactions, adverse effects, and monitoring recommendations. This presentation, part of the GHAPP MASLD & MASH Community Network and supported by Madrigal Pharmaceuticals, highlights how APPs can integrate emerging therapies into comprehensive, patient-centered management plans for MASLD and MASH.
Watch Now
Webcast: MASLD Pharmacotherapy With Marcella Pomeranz
October 2025
In this educational session, Marcella Pomeranz, DNP, explores the evolving pharmacotherapy options for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction–Associated Steatohepatitis (MASH). Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this talk reviews both established and emerging therapies—from GLP-1 receptor agonists and pioglitazone to vitamin E and the recently approved resmetirom (Rezdiffra). Marcella discusses practical considerations for treatment selection, dosing adjustments, and medication safety, along with strategies to combine pharmacologic therapy with diet, exercise, and lifestyle modification to slow fibrosis progression and improve liver outcomes.
Watch Now
Webcast: MASLD Pharmacotherapy With Jill Olmstead
September 2025
Join Jill Olmstead, DNP from Providence Health for a practical, clinician-focused overview of MASLD pharmacotherapy and new treatment horizons for hepatic steatosis. This session in the GHAPP MASLD & MASH Community Network covers the shift in nomenclature, why care must be multidisciplinary (obesity, type 2 diabetes, dyslipidemia, hypertension, cardiovascular risk), and how to stage disease with FIB-4, noninvasive tests, and FibroScan before initiating therapy. Jill reviews lifestyle and weight-loss strategies, GLP-1 receptor agonists—their mechanisms, common GI side effects, and peri-procedure considerations due to delayed gastric emptying—plus where vitamin E and pioglitazone do and don’t fit today. She also walks through practical use of resmetirom for non-cirrhotic MASH with F2–F3 fibrosis (labs to order, monitoring, drug–drug interactions, and setting expectations alongside diet and exercise). If you’re a GI/hepatology clinician, APP, or primary-care partner looking to streamline risk reduction, staging, and evidence-based therapy for MASLD/MASH, this talk delivers step-by-step guidance you can use in clinic today.
Watch Now
Webcast: MASLD vs MetALD With Maly Tiev
November 2025
In this educational session, Maly Tiev, NP from NYU Langone Health, explores the evolving understanding of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated alcohol-related liver disease (MetALD). Drawing on over 25 years of hepatology experience, she uses a real-world case to walk through the latest definitions, diagnostic criteria, and management strategies for patients with overlapping metabolic and alcohol-related liver disease. Maly explains how alcohol intake interacts with metabolic risk factors such as obesity, diabetes, and hypertension to accelerate fibrosis progression, and highlights the role of non-invasive testing—including FibroScan and the PEth test—in accurate diagnosis. The discussion also covers the clinical significance of F3 fibrosis, lifestyle interventions like the Mediterranean diet, and when to consider pharmacologic treatment such as resmetirom for patients with advanced disease. Watch to better understand how to identify, classify, and manage MASLD and MetALD in clinical practice.
Watch Now
Webcast: MASLD Pharmacotherapy With Ellie Gonyeau
September 2025
In this practical, clinician-focused talk, Ellie Gonyeau, NP, walks through a streamlined pharmacotherapy framework for MASLD/MASH—anchored on three pillars: obesity management, cardiometabolic risk reduction (T2D, hypertension, dyslipidemia), and liver-directed therapy. She reviews where GLP-1 receptor agonists fit (weight loss, glycemic control, peri-procedure considerations), summarizes evidence and patient selection for high-dose vitamin E and pioglitazone, and explains the role of resmetirom—the first FDA-approved therapy for non-cirrhotic MASH with F2–F3 fibrosis—its liver-selective THR-β mechanism, pivotal trial outcomes, common AEs, and drug-interaction/ statin considerations. You’ll also learn how to monitor and restage using non-invasive tests (FibroScan kPa/CAP, ELF, labs), set measurable lifestyle goals, and navigate real-world questions around coverage, testing cadence, and treatment duration—so you can confidently tailor therapy and improve outcomes for patients across the MASLD/MASH spectrum.
Watch Now
Webcast: MASLD vs MetALD With Whitney Steinmetz
November 2025
Join Whitney Steinmetz, NP for a practical, case-based walkthrough of the updated steatotic liver disease nomenclature—MASLD, MASH, and ALD/MetALD—and how to apply it in clinic. Using a common scenario, she covers risk stratification with FIB-4 and FibroScan (kPa/CAP), when to order PEth to quantify alcohol use, and why F3 warrants HCC screening and vaccinations. You’ll get actionable tips on counseling for weight loss and alcohol reduction, evaluating supplements, addressing cardiometabolic risks (A1C, triglycerides, BP), and considering resmetirom in appropriate non-cirrhotic patients.
Watch Now
Webcast: MASLD vs MetALD With Lavinia Iordache
September 2025
In this MASLD Community Network session, Lavinia Iordache, PA-C, clarifies the new SLD nomenclature and the distinctions between MASLD and MetALD, then walks through a real-world case (Ashley, 52) to show how to quantify alcohol intake, recognize cardiometabolic risk factors, and stage disease using non-invasive tests (FIB-4, FibroScan/VCTE with CAP, ELF). She explains how even “moderate” alcohol can accelerate fibrosis when metabolic risks are present, why PEth biomarker testing helps uncover under-reported use, and how to triage patients who land in the F3–F4 range. Practical takeaways include culturally sensitive Mediterranean-style nutrition, 5–10% weight-loss goals, tailored exercise, alcohol cessation, and when to consider resmetirom (Rezdiffra) for eligible F2–F3 non-cirrhotic patients. The talk also covers HCC surveillance (and when to prefer CT/MRI over ultrasound in central adiposity) and sets clear pathways for primary care, GI, and hepatology to work in sync.
Watch Now